Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2015

View Archived Issues

Pfizer reflects on milestones of third quarter 2015

Charleston Laboratories and Daiichi Sankyo report data from phase III study of CL-108

Emory University divulges AEP inhibitors

Immunovaccine's RSV candidate is well tolerated in phase I trial

Ultragenyx and Arcturus collaborate to develop mRNA therapeutics for rare diseases

7-Methylxanthine reduces myopia progression in children

Nano-diamino-tetraiodothyroacetic acid named orphan drug in the U.S.

OncoSec Medical starts biomarker study of ImmunoPulse IL-12 in triple-negative breast cancer

Preclinical studies of Shigellosis-typhoid bivalent vaccine

Sumitomo Dainippon offers overview of second quarter of fiscal 2015

MedImmune discloses anti-IL-21 MAbs

Zhejiang University and Shanghai Institute of Materia Medica patent proteasome inhibitors

Bayer Schering Pharma reports CDK9/cyclin-T1 inhibitors

Sanofi introduces GPR119 agonists

Isis Pharmaceuticals divulges SOD-1 modified ASOs

Ferring's Rekovelle MAA filing accepted by EMA

Mochida files NDA for MD-0901 for ulcerative colitis in Japan

Memory and learning deficits restored using neurotrophic factor mimetic in AD aged mice

PLX-3397 receives FDA breakthrough therapy designation for tenosynovial giant cell tumor

Porcupine inhibitor blocks growth of Wnt-upregulated tumors in mice

Researchers create refined animal model of experimental autoimmune encephalomyelitis

Canbex Therapeutics initiates phase II trial of VSN-16R for spasticity in MS

Cellceutix updates status of brilacidin program

Novel assay for the diagnosis of MKD demonstrates 100% accuracy

Chugai describes phase I candidate PTH1 receptor agonist PCO-371

Merck KGaA and Selvita extend cancer drug discovery collaboration

AbbVie applies for approval of new indication for Humira in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...